Hetiamacin E and F, New Amicoumacin Antibiotics from Bacillus subtilis PJS Using MS/MS-Based Molecular Networking

Molecules. 2020 Sep 27;25(19):4446. doi: 10.3390/molecules25194446.

Abstract

To combat escalating levels of antibiotic resistance, novel strategies are developed to address the everlasting demand for new antibiotics. This study aimed at investigating amicoumacin antibiotics from the desert-derived Bacillus subtilis PJS by using the modern MS/MS-based molecular networking approach. Two new amicoumacins, namely hetiamacin E (1) and hetiamacin F (2), were finally isolated. The planar structures were determined by analysis of extensive NMR spectroscopic and HR-ESI-MS data, and the absolute configurations were concluded by analysis of the CD spectrum. Hetiamacin E (1) showed strong antibacterial activities against methicillin-sensitive and resistant Staphylococcus epidermidis at 2-4 µg/mL, and methicillin-sensitive and resistant Staphylococcus aureus at 8-16 µg/mL. Hetiamacin F (2) exhibited moderate antibacterial activities against Staphylococcus sp. at 32 µg/mL. Both compounds were inhibitors of protein biosynthesis demonstrated by a double fluorescent protein reporter system.

Keywords: Bacillus subtilis PJS; amicoumacins; antibacterial activity; inhibitors of protein biosynthesis; methicillin-resistant Staphylococcus aureus (MRSA).

MeSH terms

  • Anti-Bacterial Agents* / chemistry
  • Anti-Bacterial Agents* / isolation & purification
  • Anti-Bacterial Agents* / pharmacology
  • Bacillus subtilis / chemistry*
  • Coumarins* / chemistry
  • Coumarins* / isolation & purification
  • Coumarins* / pharmacology
  • Mass Spectrometry
  • Methicillin-Resistant Staphylococcus aureus / growth & development*
  • Nuclear Magnetic Resonance, Biomolecular

Substances

  • Anti-Bacterial Agents
  • Coumarins